Lung cancer is among the most common types of cancers prevailing all over the world. A new study by Tulane University has found a molecular pathway to stop lung cancer spread. The research has been published in Proceedings of the National Academy of Sciences and it could lead to the development of new anticancer drug and more personalized treatment for lung cancer. In this study, they found that a known tumor suppressor protein called RBM10 can inhibit lung cancer growth by suppressing the function of a protein that is responsible for driving cancer cell growth. This protein is called c-Myc. The research team has discovered thar RBM10 partners with two ribosomal proteins to destabilize c-Myc and inhibit lung cancer spread.
In this study, the researchers found that a mutant form of RBM10 that is often found in lung cancers loses the ability to suppress c-Myc. RBM10 is an improtant protein that can suppress cancer cells. These findings are the first to identify a cancer inhibitory relationship between the proteins.
RBM10 is an important protein that can suppress cancer cells, but when a cancer wants to develop, it will mutate RBM10 and block that function,” Lu said. They aim to further study on how the RBM10 mutant functions in hope of developing an anticancer drug to target it. The team is hopeful in designing a module to specifcally target the mutant and if that mutant is converted, they can hopefully make it suppress the cancer-causing activity of c-Myc.
The informatio shared in this blog is for educational purposes only.